At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 139 enrolled
Drug / intervention
AZD0530 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomised, Open-Label, Pilot Study to Evaluate the Safety and Effects on Bone Resorption of AZD0530 in Patients With Prostate Cancer or Breast Cancer With Metastatic Bone Disease.
In Brief
A Phase 2 clinical trial evaluating AZD0530 and Zoledronic Acid for Breast Cancer and 2 related conditions. Completed, enrolled 139 participants across 28 sites in 8 countries.
Detailed Summary
The purpose of this study is to determine the effect of AZD0530 on subjects with breast cancer or prostate cancer with metastatic bone disease in comparison to zoledronic acid.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Prostate Cancer, Bone Neoplasms
CountriesCanada, Denmark, Norway, Portugal, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 2007
Enrollment StartFeb 2008
Primary CompletionJan 2010
Study CompletionAug 2012
TodayJul 2026
First PostedNov 14, 2007
Enrollment StartFeb 1, 2008
Primary CompletionJan 1, 2010
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.6 years ago
Interventions
AZD0530drug
Daily oral dose
Zoledronic Aciddrug